Novartis AG
COMBINATIONS OF THE CDK4/6 INHIBITOR LEE011 AND THE MEK1/2 INHIBITOR TRAMETINIB, OPTIONALLY FURTHER COMPRISING THE PI3K INHIBITOR BYL719 TO TREAT CANCER

Abstract:

The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a mitogen activated protein kinase (MEK) inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3-kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.